<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1613">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04800120</url>
  </required_header>
  <id_info>
    <org_study_id>IRB Protocol #00800</org_study_id>
    <nct_id>NCT04800120</nct_id>
  </id_info>
  <brief_title>Use of Hyperbaric Oxygen Therapy to Treat COVID-19 Patients With Respiratory Distress</brief_title>
  <acronym>HBOT</acronym>
  <official_title>The Use of Hyperbaric Oxygen Therapy (HBOT) for the Treatment of COVID-19 Patients With Mild-to-moderate Respiratory Distress</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steward St. Elizabeth's Medical Center of Boston, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Steward St. Elizabeth's Medical Center of Boston, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigate whether hyperbaric oxygen therapy treatment can become a viable treatment option&#xD;
      for COVID-19. If successful, providers will be able to provide future COVID-19 patients with&#xD;
      mild-to-moderate respiratory distress hyperbaric oxygen therapy in order to help avoid&#xD;
      mechanical ventilation&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Using the Monoplace Hyperbaric Oxygen Chambers we will be providing COVID- 19 positive&#xD;
      patients with mild-to-moderate distress 100% oxygen at 2.0 ATA for 90 minutes on consecutive&#xD;
      days for a total of up to 5 treatments. A comparison will be made using a historical cohort&#xD;
      not receiving HBOT. Data will be collected to determine whether or not HBOT is of any benefit&#xD;
      to COVID-19 positive patient with mild-to-moderate respiratory distress.&#xD;
&#xD;
      Study Group: Provide 100% oxygen at 2.0 ATA for 90 minutes on consecutive days for a total of&#xD;
      up to 5 treatment to COVID-19 patients meeting inclusion criteria Control Group: Any COVID-19&#xD;
      positive patient meeting study inclusion criteria that does not receive HBOT (historical) The&#xD;
      control group is further defined as patients who were previously treated for COVID-19 at&#xD;
      Morton Hospital that did not receive hyperbaric oxygen therapy. This will require accessing&#xD;
      medical records to obtain patient information to establish the historical control data&#xD;
      metric.&#xD;
&#xD;
      Study outcome measures:&#xD;
&#xD;
        -  Time to normalize 02 requirement (ambient air pulse ox greater than or equal to 92% or&#xD;
           ABG w/Pa02 greater than 60mmHG on air)&#xD;
&#xD;
        -  Mortality&#xD;
&#xD;
        -  Days free of invasive mechanical ventilation&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Study Group: Provide 100% oxygen at 2.0 ATA for 90 minutes on consecutive days for a total of up to 5 treatment to COVID-19 patients meeting inclusion criteria Control Group: Any COVID-19 positive patient meeting study inclusion criteria that does not receive HBOT (historical)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Normalization of oxygen</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>normalize 02 requirement (ambient air pulse ox greater than or equal to 92% or ABG w/Pa02 greater than 60mmHG on air)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Patient survival of COVID-19</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days free of invasive mechanical ventilation</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>The time which patient remains without the need for intubation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Identified COVID 19 patients receiving the intervention of Hyperbaric Oxygen Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Historical control of COVID 19 patients who were previously treated and did not receiving Hyperbaric Oxygen Therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hyperbaric Oxygen Therapy</intervention_name>
    <description>Delivery of 100% oxygen within a hyperbaric oxygen therapy chamber</description>
    <arm_group_label>Study Group</arm_group_label>
    <other_name>HBOT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Verified COVID-19 infection&#xD;
&#xD;
          -  Patient w/02 dependence of less than or equal to 6 liter/min to maintain pulse ox&#xD;
             greater than or equal to 92% or arterial gas w/PA02 greater than 60mm HG&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not diagnosed w/COVID-19 infection&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  DNR or other restrictions in escalation of level of care&#xD;
&#xD;
          -  Contraindication for HBO&#xD;
&#xD;
          -  Blood pressure parameters which are deemed unstable by clinical team&#xD;
&#xD;
          -  Patients who require continuous ECG and/or continuous blood pressure monitoring, and&#xD;
             with arterial lines&#xD;
&#xD;
          -  Patients requiring rewarming&#xD;
&#xD;
          -  Patients requiring any kind of invasive catheter/pressure monitoring&#xD;
&#xD;
          -  Patients requiring continuous support of intravenous medication&#xD;
&#xD;
          -  Minor subject (less than 18 years old)&#xD;
&#xD;
          -  Refusal to participate&#xD;
&#xD;
          -  Signs of respiratory decompensation requiring intubation and mechanical ventilation&#xD;
&#xD;
          -  02 dependence greater than or equal to 6L/minute to obtain Sa02 greater than or equal&#xD;
             to 92% or ABG w/Pa02 &gt;60mmHg&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jill Trelease, DNP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Steward Healthcare</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jill Trelease, DNP</last_name>
    <phone>508-828-7000</phone>
    <email>jill.trelease@steward.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Morton Hospital</name>
      <address>
        <city>Taunton</city>
        <state>Massachusetts</state>
        <zip>02780</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Pfeiffer, MPH</last_name>
      <phone>508-828-7000</phone>
      <phone_ext>7363</phone_ext>
      <email>patricia.pfeiffer@steward.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 13, 2020</study_first_submitted>
  <study_first_submitted_qc>March 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Steward St. Elizabeth's Medical Center of Boston, Inc.</investigator_affiliation>
    <investigator_full_name>Jill Trelease</investigator_full_name>
    <investigator_title>Program Director, Center for Wound Healing at Morton Hospital</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

